Phaseline

Targets › PVRL4

PVRL4 (Nectin-4): drug programs, companies and trials

3 programs from 2 companies in 6 trials: 5 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.; FUNCTION: (Microbial infection) Acts as a receptor for measles virus. (UniProt, Q96NY8)

Open in Phaseline: the race on PVRL4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fudan UniversitySHR-A2102
Nectin4-directed antibody-drug conjugate
PVRL4Phase 2Triple-negative Breast Cancer; Pancreatic Cancer; Advanced Breast CancerDec 2026
Fudan University9MW2821
Nectin4-directed antibody-drug conjugate
PVRL4Phase 2Advanced Breast CancerSep 2027
Eastern Hepatobiliary Surgery HospitalSuper Hi-TCR-T cells
Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP
PVRL4, KLRC1, TROP2, B7H3, GPC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Jan 2028

Conditions

Pancreatic Cancer (2) Advanced Breast Cancer (2) Triple-negative Breast Cancer (1) Advanced Hepatocellular Carcinoma (HCC) (1)

Modalities

mixed (2), other (1)

Companies

Fudan University (2) Eastern Hepatobiliary Surgery Hospital (1)

Related targets

KLRC1 (1) TROP2 (1) B7H3 (1) GPC3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.